Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
TAVEGIL TABLETS.
| Pharmaceutical Form |
|---|
|
White, uncoated, round, 7 mm in diameter with beveled edges, smooth on one side and marked with “OT” and scored with a single breakline on the other. |
Clemastine hydrogen fumarate 1.34mg (equivalent to clemastine base 1mg).
For excipients see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Clemastine |
Clemastine is an H1-receptor antagonist. It inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action. |
| List of Excipients |
|---|
|
Lactose monohydrate |
PVC/PVDC blister pack (50 or 60 tablets).
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
PL 44673/0179
08 June 2000
| Drug | Countries | |
|---|---|---|
| TAVEGIL | Germany, Estonia, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
